Skip to main content
Insulin resistance is a state in which peripheral tissues — skeletal muscle, adipose tissue and liver — require a higher-than-normal concentration of circulating insulin to maintain glucose uptake and suppress hepatic glucose output. It usually improves with targeted weight loss and habit changes. A doctor’s role in an online consultation is to assess whether adding a medicine would speed that process up — not to replace the habit changes themselves.

​
What is happening at the cellular level

Insulin binding to the insulin receptor on myocytes and adipocytes triggers autophosphorylation of the receptor’s β-subunit, which recruits and phosphorylates insulin receptor substrate (IRS) proteins — principally IRS-1. Phosphorylated IRS-1 activates phosphatidylinositol 3-kinase (PI3K), which generates PIP₃ at the membrane. PIP₃ recruits Akt (protein kinase B), and activated Akt translocates the glucose transporter GLUT4 from intracellular vesicles to the plasma membrane, enabling glucose entry. In the insulin-resistant state, several mechanisms disrupt this chain. Excess free fatty acids — often from expanded visceral adipose tissue — activate serine/threonine kinases (including PKC-θ and JNK) that phosphorylate IRS-1 on inhibitory serine residues, blocking its ability to activate PI3K. Intramyocellular lipid accumulation (diacylglycerols and ceramides) further impairs insulin signalling in skeletal muscle (Chandrasekaran & Weiskirchen, Curr Tissue Microenviron Rep 2024). In the liver, insulin fails to suppress gluconeogenesis while continuing to drive lipogenesis, a phenomenon called selective hepatic insulin resistance.

​
How it is identified

There is no single diagnostic threshold for insulin resistance. In clinical practice the most commonly used surrogates are fasting plasma insulin, the homeostasis model assessment of insulin resistance (HOMA-IR: fasting glucose × fasting insulin / 22.5), and the presence of clinical features — raised triglycerides, low HDL cholesterol, central adiposity and raised fasting glucose — that overlap with metabolic syndrome. A doctor evaluating a consultation will typically work from the combination of anthropometry, reported history and, where available, recent blood results rather than from one isolated marker.

​
Why GLP-1 agonists improve it

GLP-1 receptor agonists such as semaglutide and liraglutide improve insulin sensitivity through at least three pathways: they reduce body weight (and therefore visceral adipose tissue, the primary driver of lipotoxic insulin resistance); they slow gastric emptying, which blunts postprandial glucose excursions and the insulin demand they trigger; and they have weight-independent effects on β-cell function — enhancing glucose-stimulated insulin secretion in a glucose-dependent manner via cAMP-mediated signalling in pancreatic β-cells. The dual GLP-1/GIP agonist tirzepatide adds GIP receptor agonism, which may further enhance insulin sensitivity in adipose tissue.

​
Treatments a doctor considers

A licensed doctor decides case by case and never prescribes without evaluation:

Semaglutide (Wegovy / Ozempic)

Weekly GLP-1 receptor agonist. A doctor may prescribe it if your BMI and history match the indications. Requires follow-up.

Tirzepatide (Mounjaro)

Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities and your BMI.

Liraglutide (Saxenda)

Daily GLP-1 agonist. Indicated in selected patients with elevated BMI after medical evaluation.

Orlistat 120mg

Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider based on your history. See the Xenical (orlistat) guide.
Rybelsus (oral semaglutide) — a once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.
You pay for any medication separately at the pharmacy you choose — Hi-Doctor does not sell medications. See pricing for the consultation fee.

​
Your path to treatment

1

Start your online visit

Answer a 4-minute questionnaire about your health and goal. No in-person appointment, no travel — you will know within 24 hours if you are a candidate.
2

A doctor reviews your case

A licensed doctor reviews your answers personally. If they need clarification, they message you in the private chat on your account. If treatment is appropriate, they sign an electronic prescription.
3

Review and payment

If the doctor does not approve treatment, the consultation fee is refunded in full within 48 hours.
4

Ongoing support

Private chat with your doctor for questions, a 4-week check-in, and renewal before your prescription expires.

​
How Hi-Doctor handles it

Every case is reviewed by a licensed EU doctor, with renewals reviewed on an ongoing basis and support available through your private account chat. See how a consultation works, the treatment areas Hi-Doctor covers, and how eligibility is decided in safety. For a medicine outside EU authorisation that some people ask about for weight management, see the orforglipron page.

​
Common questions

Insulin resistance is an early marker on the road to type 2 diabetes. It usually improves with targeted weight loss and habit changes. A doctor assesses whether adding a medicine would speed that process up.
The doctor reviews your questionnaire answers, including your BMI, weight history and overall health. They assess which treatment options, if any, are appropriate for your case and rule out contraindications.
A doctor may consider semaglutide, tirzepatide, liraglutide or orlistat, depending on your BMI, history and any other health conditions you have. The decision is made case by case.
Results depend on the treatment chosen and your individual response. The doctor monitors progress at regular reviews and adjusts the approach if needed.
A licensed doctor evaluates your case against the authorised indications for each medicine, including BMI criteria and associated risk factors. If you are not a candidate, the doctor explains why and the consultation fee is refunded.

​
Start a consultation

Weight-loss consultation

Answer the weight-loss questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.